Enlaza Therapeutics key facts
as of Oct 2026- Developer of covalent protein therapeutics intended to deliver efficacious and safer treatments.
- Enlaza Therapeutics is valued at approximately $295.0M as of Oct 2026, set at its later-stage round, Sep 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $176.0M across 3 recorded rounds; the latest was Early Stage VC ($15.0M) in Aug 2025.
- Notable investors include Lightspeed Venture Partners, Alexandria Venture Investments, Samsara BioCapital, Pfizer Ventures, Frazier Healthcare Partners — 13 tracked in total.
- Enlaza Therapeutics has filed 8 Form Ds with the SEC since 2021, most recently Sep 2025 ($15.0M sold to 1 investors).
- Status: Privately Held (backing).
Valued at $295.0M at its later-stage round, Sep 2025. Nothing has traded since.
- ·The complete investor list: 13 names
- ·Watch Enlaza Therapeutics: the Monday email on marks, rounds and moves
Enlaza Therapeutics funding rounds
3 roundsWho backs Enlaza Therapeutics
13+Enlaza Therapeutics valuation
Enlaza Therapeutics was valued at $295 million at its later-stage round in Sep 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Enlaza Therapeutics raised?
Enlaza Therapeutics has raised $176 million across 3 recorded rounds since 2021. The largest was an $84 million later-stage round in Apr 2024; the most recent was a $15 million early-stage round in Aug 2025.
Enlaza Therapeutics has filed 8 Form Ds with the SEC since 2021, most recently in Sep 2025 ($15 million sold to 1 investor).
Enlaza Therapeutics investors
13 investors are on record for Enlaza Therapeutics, including Lightspeed Venture Partners, Alexandria Venture Investments, Samsara BioCapital and Pfizer Ventures. The early-stage round in Aug 2025 drew 1 investor.
About Enlaza Therapeutics
Developer of covalent protein therapeutics intended to deliver efficacious and safer treatments. The company offers a novel synthetic biology platform that uses covalent bonds to lock onto a target protein to provide sustained occupancy and prolonged biologic effect with minimal systemic exposure, enabling healthcare professionals to treat various diseases.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2020
- Employees
- 55
- Website
- enlazatx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.